The Brain Tumour Foundation of Canada has posted detailed information on its website (see link below). Temozolomide is produced in both brand and generic form and has been long approved for funding on provincial formularies. The issue is not its funding, but in HOW that funding is accessed.
The hope is that this roadmap may serve as a resource to those shaping a national system of pharmacare to demonstrate why a consistent, standardized and monitored method of drug access is essential to maintaining standard of care for cancer in Canada.
Currently, in Canada, Temozolomide is funded in one of three ways:
- The province takes responsibility for funding (100%)
- Technically it’s the responsibility of the patient to pay, but the province or hospital offers alternative funding
- It is considered a prescription and is a patient’s responsibility to pay.